Top Markets
Coin of the day
Noxopharm Limited Noxopharm Limited

Noxopharm Limited

NOX
株式のランク #31262
Noxopharm Limited is an Australian drug development company with an... Noxopharm Limited is an Australian drug development company with an international reach, focused on pioneering new treatment options for a range of solid tumor cancers and septic shock. Its primary asset, Veyonda, functions as an adjuvant therapy designed to augment the effectiveness of chemotherapy and radiotherapy in treating late-stage cancers. Beyond Veyonda, the company's robust development pipeline encompasses several key programs: The DARRT program, currently in Phase 1b/2a clinical trials, is addressing metastatic castration-resistant prostate cancer and other solid tumors. The LuPIN program explores a combined therapy of Veyonda and 177Lu-PSMA-617 for advanced prostate cancer. The IONIC program combines Veyonda with Bristol Myers Squibb's checkpoint inhibitor, Opdivo, targeting various solid tumor types. Its Chemotherapy Enhancement Program (CEP) integrates Veyonda with carboplatin for patients suffering from refractory solid tumors in areas such as the breast, head and neck, lung, prostate, and ovaries. Furthermore, the NOXCOVID Program is conducting a dose escalation and expansion study of NOX66 for the treatment of COVID-19 infection. The company is also investigating potential treatments for pancreatic cancer and glioblastoma. Noxopharm collaborates with the Hudson Institute of Medical Research and The Australian National University on the research and development of therapeutic drugs for inflammatory disorders. Incorporated in 2015, the company's operations are based in Chatswood, Australia.
株価
$0.04443294
時価総額
$13.65M
変化(1日)
0.00%
変化(1年)
-32.53%
国
AU
取引 Noxopharm Limited (NOX)

カテゴリー

Noxopharm Limited(NOX)のP/E比率
September 2026 時点のP/E比率 TTM -4.90
Noxopharm Limited の最新の財務報告および株価によると、現在の P/E (TTM) は -4.90 です。2024 年末時点での P/E は -5.39 でした。
Noxopharm Limited の P/E 比率の履歴(2016 〜 2026)
各年末のP/E比率
年 P/E比率 変化
2026 (TTM) -4.90 51.76%
2025 -3.23 -40.02%
2024 -5.39 545.91%
2023 -0.83 -72.57%
2022 -3.04 -83.29%
2021 -18.21 -78.30%
2020 -83.90 1,577.80%
2019 -5.00 42.59%
2018 -3.51 -62.16%
2017 -9.27 19.11%
2016 -7.78 0.00%
類似企業や競合他社のP/E比率
企業 P/E比率 P/E比率の差 国
29.99 -711.89%
US
-18.38 274.99%
US
-23.34 376.08%
AU
36.30 -840.42%
NL
- -
CH
P/E比率の読み方

株価収益率(P/E Ratio)は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の(0に近い)P/Eは、損失が大きいことを示します。

P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。

10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。